Financials in GBp. Standardized financial statements.
A compact view of how Shield Therapeutics plc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £50.74M | £31.51M | £16.54M | £5.50M | £1.52M | £10.39M | £719,000 | £11.88M | £637,000 | £304,000 |
| Revenue Growth? | +61.1% | +90.5% | +200.8% | +262.0% | -85.4% | +1344.6% | -93.9% | +1765.1% | +109.5% | 0.0% |
| Cost of Revenue? | £28.36M | £18.29M | £11.45M | £3.04M | £980,000 | £4.06M | £485,000 | £311,000 | £155,000 | £100,000 |
| Gross Profit? | £22.38M | £13.22M | £5.09M | £2.46M | -£1.67M | £6.33M | £234,000 | £11.57M | £482,000 | £204,000 |
| Gross Margin? | +44.1% | +42.0% | +30.8% | +44.7% | -109.8% | +60.9% | +32.5% | +97.4% | +75.7% | +67.1% |
| Operating Expenses? | £32.68M | £37.80M | £44.69M | £52.21M | £20.49M | £8.48M | £9.27M | £16.74M | £21.43M | £12.66M |
| Operating Income? | -£10.30M | -£22.87M | -£39.60M | -£26.39M | -£20.41M | -£2.15M | -£9.04M | -£5.17M | -£20.95M | -£12.46M |
| EBITDA? | -£10.30M | -£20.74M | -£38.28M | -£46.07M | -£17.69M | £820,000 | -£9.26M | -£2.47M | -£18.54M | -£10.40M |
| Income Before Tax | -£17.50M | -£26.00M | -£40.92M | -£40.08M | -£19.91M | -£1.89M | -£9.07M | -£5.15M | -£20.99M | -£15.60M |
| Income Tax Expense | £524,783 | £612,927 | £1.16M | £362,077 | -£229,000 | £744,000 | -£266,000 | -£3.36M | -£1.41M | -£587,000 |
| Net Income? | -£18.03M | -£26.61M | -£33.29M | -£40.44M | -£19.34M | -£2.63M | -£8.80M | -£1.79M | -£19.59M | -£15.02M |
| EPS? | £-0.02 | £-0.03 | £-0.05 | £-0.17 | £-0.09 | £-0.02 | £-0.07 | £-0.01 | £-0.17 | £-0.18 |
| Diluted EPS? | £-0.02 | £-0.03 | £-0.05 | £-0.17 | £-0.09 | £-0.02 | £-0.07 | £-0.01 | £-0.17 | £-0.18 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality